查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
欧洲新兴感染疾病诊断市场：分析与预测（2023-2033）
市场调查报告书
商品编码
1419002

欧洲新兴感染疾病诊断市场：分析与预测（2023-2033）

Europe Emerging Infectious Disease Diagnostics Market: Analysis and Forecast, 2023-2033
出版日期: | 出版商: BIS Research | 英文 127 Pages | 商品交期: 1-5个工作天内

价格

欧洲新兴感染疾病诊断市场规模预计将从 2023 年的 47 亿美元增至 2033 年的 78.5 亿美元，预测期内复合年增长率为 5.28%。

由于几个关键因素，市场正在成长。这些因素包括感染疾病的经济影响、政府透过资金和伙伴关係提供的财政支持、对现场护理和综合征检测的需求增加以及分子​​诊断技术的进步。

主要市场统计数据
预测期 2023-2033
2023年评估 47亿美元
2033年预测 78.5亿美元
复合年增长率 5.28%

欧洲新兴感染疾病诊断市场的特点是有多种旨在快速、准确地识别和检测传染源的方法和技术。该领域在及时诊断疾病、促进适当的治疗决策和公共卫生应对方面发挥着重要作用。在欧洲，微生物培养仍然是基本方法，其中患者检体在特殊的生长介质中生长以分离和鑑定特定的病原体。这使我们能够准确识别致病微生物并评估其对抗生素的敏感性。此外，迅速发展的分子诊断也受到关注。聚合酶链反应（PCR）和核酸增幅检查（NAAT）等技术已被广泛采用，即使在低浓度下也可以灵敏且特异性识别病原体。由于技术进步和对公共卫生的日益关注，欧洲新兴感染疾病诊断市场预计将继续发展和创新。

本报告调查了欧洲新兴的感染疾病诊断市场，并提供了市场概况、对市场成长的各种影响因素的分析、专利和管道的趋势、法律制度、市场规模趋势和预测以及主要国家的细分。总结了详细分析、主要企业分析等。

市场分类

细分1：按用途

  • 试验
  • 即时检测

细分 2：依技术分类

  • 聚合酶炼式反应 (PCR)
  • 恒温核酸增幅技术（INAAT）
  • 次世代定序仪(NGS)
  • 免疫诊断
  • 其他的

细分 3：依感染类型

  • 细菌
  • 病毒
  • 菌
  • 其他的

细分 4：依疾病类型

  • 呼吸道感染疾病
  • 性行为感染感染（STI）
  • 胃肠道感染疾病
  • 其他的

细分 5：依最终使用者分类

  • 医院/诊所
  • 诊断实验室
  • 其他的

细分 6：按国家/地区划分

  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 其他的

目录

执行摘要

调查范围

调查方法

第一章 市场

  • 市场展望
  • 产业展望
    • 市场概况
    • 专利分析
    • 管道分析
    • COVID-19 对感染疾病诊断的影响
    • 供应链分析
  • 市场动态
    • 影响分析
    • 促进因素
    • 抑制因素
    • 机会

第二章 新兴感染疾病诊断市场（分地区）

  • 欧洲新兴的感染疾病诊断市场
    • 法律规范
    • 市场动态
    • 市场规模/预测

第三章市场：竞争基准化分析/公司简介

  • 竞争形势
    • 概述
    • 经营策略
    • 经营策略
  • 市场占有率分析
  • 新兴感染疾病诊断生态系中的活跃公司
  • 公司简介
    • bioMerieux SA
    • DiaSorin SpA
    • F. Hoffmann-La Roche Ltd
    • QIAGEN NV
    • Tecan Trading AG
    • Siemens Healthineers AG
  • 企业概况
    • En Carta Diagnostics
Product Code: BHP1838SS

“The Europe Emerging Infectious Disease Diagnostics Market Expected to Reach $7.85 Billion by 2033.”

Introduction to Europe Emerging Infectious Disease Diagnostics Market

The Europe emerging infectious disease diagnostics market was valued at $4.70 billion in 2023 and is expected to reach $7.85 billion by 2033, growing at a CAGR of 5.28% between 2023 and 2033. The market for diagnosing emerging infectious diseases is experiencing growth due to several key factors. These factors encompass the economic impact of infectious diseases, financial support from governments through funding and partnerships, rising demand for point-of-care and syndromic testing, and advancements in molecular diagnostics technology.

KEY MARKET STATISTICS
Forecast Period2023 - 2033
2023 Evaluation$4.70 Billion
2033 Forecast$7.85 Billion
CAGR5.28%

Market Introduction

The European emerging infectious disease diagnostics market is characterized by a diverse array of methods and techniques aimed at identifying and detecting infectious agents swiftly and accurately. This sector plays a crucial role in the timely diagnosis of diseases, facilitating appropriate treatment decisions and public health responses. Within Europe, microbiological culture remains a fundamental method, involving the cultivation of patient specimens on specialized growth media to isolate and identify specific pathogens. This allows for the precise determination of the causative organism and an assessment of its susceptibility to antimicrobial agents. In addition, molecular diagnostics, a rapidly evolving field, is gaining prominence. Techniques like polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs) are extensively employed, offering highly sensitive and specific pathogen identification, even at low concentrations. With ongoing technological advancements and a growing emphasis on public health, the European market for emerging infectious disease diagnostics is poised for continuous development and innovation.

Market Segmentation:

Segmentation 1: by Application

  • Laboratory Testing
  • Point-of-Care Testing

Segmentation 2: by Technology

  • Polymerase Chain Reaction (PCR)
  • Isothermal Nucleic Acid Amplification Technology (INAAT)
  • Next-Generation Sequencing (NGS)
  • Immunodiagnostics
  • Other Technologies

Segmentation 3: by Type of Infection

  • Bacterial
  • Viral
  • Fungal
  • Other Infections

Segmentation 4: by Disease Type

  • Respiratory Infections
  • Sexually Transmitted Infections (STIs)
  • Gastrointestinal Infections
  • Other Infections

Segmentation 5: by End User

  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Other End Users

Segmentation 6: by Country

  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest-of-Europe

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: The Europe emerging infectious disease diagnostics market has been extensively segmented on the basis of various categories, such as application, technology, type of infection, disease type, end user, and region. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Competitive Strategy: The Europe emerging infectious disease diagnostics market is fragmented, with several established as well as emerging players. Key players in the Europe emerging infectious disease diagnostics market analyzed and profiled in the study involve established players that offer various kinds of molecular diagnostic tests for infectious diseases.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and regional presence.

Some of the prominent names in this market are:

  • bioMerieux S.A
  • DiaSorin S.p.A
  • F. Hoffmann-La Roche Ltd.
  • QIAGEN N.V.
  • Tecan Trading AG
  • Siemens Healthineers AG

Table of Contents

Executive Summary

Scope of the Study

Research Methodology

1. Markets

  • 1.1. Market Outlook
    • 1.1.1. Product Definition
    • 1.1.2. Inclusion and Exclusion Criteria
    • 1.1.3. Key Findings
  • 1.2. Industry Outlook
    • 1.2.1. Market Overview
      • 1.2.1.1. Timeline of Emerging Technologies for Infectious Disease Diagnostics
      • 1.2.1.2. Advantages and Limitations of Emerging Infectious Disease Diagnostic Technologies
      • 1.2.1.3. Advantages and Limitations of Point-of-Care Emerging Infectious Disease Diagnostics
      • 1.2.1.4. Current Market Landscape of Emerging Infectious Disease Diagnostics
      • 1.2.1.5. Future Potential
        • 1.2.1.5.1. CRISPR
        • 1.2.1.5.2. NGS
        • 1.2.1.5.3. INAAT
        • 1.2.1.5.4. Digital PCR (dPCR)
    • 1.2.2. Patent Analysis
      • 1.2.2.1. By Year
      • 1.2.2.2. By Country/Organization
    • 1.2.3. Pipeline Analysis
    • 1.2.4. Impact of COVID-19 on Infectious Disease Diagnostics
      • 1.2.4.1. Post-COVID-19 Scenario: A Paradigm Shift to Home-Based Testing
    • 1.2.5. Supply Chain Analysis
  • 1.3. Market Dynamics
    • 1.3.1. Impact Analysis
    • 1.3.2. Drivers
      • 1.3.2.1. Economic Burden of Infectious Diseases
      • 1.3.2.2. Government Support to Advance Research and Facilitate Early Diagnosis of Infectious Diseases Through Funding and Collaboration
      • 1.3.2.3. Increasing Demand for Point-of-Care (POC) and Syndromic Testing
      • 1.3.2.4. Technological Advancements in Molecular Diagnostics
        • 1.3.2.4.1. Isothermal Nucleic Acid Amplification Techniques (INAATs)
        • 1.3.2.4.2. Digital PCR
        • 1.3.2.4.3. CRISPR Technologies
    • 1.3.3. Restraints
      • 1.3.3.1. Poor Reimbursement for Molecular Diagnostic Tests for Infectious Diseases
      • 1.3.3.2. Erratic Trend in Infectious Disease Epidemic Outbreaks Globally
      • 1.3.3.3. Lack of an Established Framework for NGS-based Tests for Infectious Diseases
    • 1.3.4. Opportunities
      • 1.3.4.1. Potential of Molecular Diagnostic Tests in Low-Resource Settings
      • 1.3.4.2. Potential of Rapid Point-of-Care Tests in Managing Antimicrobial Resistance

2. Emerging Infectious Disease Diagnostics Market (by Region)

  • 2.1. Europe Emerging Infectious Disease Diagnostics Market
    • 2.1.1. Regulatory Framework
    • 2.1.2. Market Dynamics
      • 2.1.2.1. Impact Analysis
    • 2.1.3. Market Sizing and Forecast
      • 2.1.3.1. Europe Emerging Infectious Disease Diagnostics Market (by Application)
      • 2.1.3.2. Europe Emerging Infectious Disease Diagnostics Market (by Technology)
      • 2.1.3.3. Europe Emerging Infectious Disease Diagnostics Market (by Type of Infection)
      • 2.1.3.4. Europe Emerging Infectious Disease Diagnostics Market (by Disease Type)
      • 2.1.3.5. Europe Emerging Infectious Disease Diagnostics Market (by End User)
        • 2.1.3.5.1. Germany
          • 2.1.3.5.1.1. Market Dynamics
          • 2.1.3.5.1.2. Market Size and Forecast
          • 2.1.3.5.1.2.1. Germany Emerging Infectious Disease Diagnostics Market (by End User)
        • 2.1.3.5.2. U.K.
          • 2.1.3.5.2.1. Market Dynamics
          • 2.1.3.5.2.2. Market Size and Forecast
          • 2.1.3.5.2.2.1. U.K. Emerging Infectious Disease Diagnostics Market (by End User)
        • 2.1.3.5.3. France
          • 2.1.3.5.3.1. Market Dynamics
          • 2.1.3.5.3.2. Market Size and Forecast
          • 2.1.3.5.3.2.1. France Emerging Infectious Disease Diagnostics Market (by End User)
        • 2.1.3.5.4. Italy
          • 2.1.3.5.4.1. Market Dynamics
          • 2.1.3.5.4.2. Market Size and Forecast
          • 2.1.3.5.4.2.1. Italy Emerging Infectious Disease Diagnostics Market (by End User)
        • 2.1.3.5.5. Spain
          • 2.1.3.5.5.1. Market Dynamics
          • 2.1.3.5.5.2. Market Size and Forecast
          • 2.1.3.5.5.2.1. Spain Emerging Infectious Disease Diagnostics Market (by End User)
        • 2.1.3.5.6. Rest-of-Europe
          • 2.1.3.5.6.1. Market Dynamics
          • 2.1.3.5.6.2. Market Size and Forecast
          • 2.1.3.5.6.2.1. Rest-of-Europe Emerging Infectious Disease Diagnostics Market (by End User)

3. Markets - Competitive Benchmarking & Company Profiles

  • 3.1. Competitive Landscape
    • 3.1.1. Overview
    • 3.1.2. Corporate Strategies
      • 3.1.2.1. Mergers and Acquisitions
      • 3.1.2.2. Synergistic Activities
      • 3.1.2.3. Business Expansions and Funding
    • 3.1.3. Business Strategies
      • 3.1.3.1. Product Launches/Upgradations/Approvals
  • 3.2. Market Share Analysis
  • 3.3. Emerging Infectious Disease Diagnostics Ecosystem Active Players
  • 3.4. Company Profiles
    • 3.4.1. bioMerieux S.A.
      • 3.4.1.1. Company Overview
      • 3.4.1.2. Role of bioMerieux S.A. in the Emerging Infectious Disease Diagnostics Market
      • 3.4.1.3. Financials
      • 3.4.1.1. Recent Developments
      • 3.4.1.2. Analyst Perspective
    • 3.4.2. DiaSorin S.p.A.
      • 3.4.2.1. Company Overview
      • 3.4.2.2. Role of DiaSorin S.p.A. in the Emerging Infectious Disease Diagnostics Market
      • 3.4.2.3. Financials
      • 3.4.2.4. Recent Developments
      • 3.4.2.5. Analyst Perspective
    • 3.4.3. F. Hoffmann-La Roche Ltd
      • 3.4.3.1. Company Overview
      • 3.4.3.2. Role of F. Hoffmann-La Roche Ltd in the Emerging Infectious Disease Diagnostics Market
      • 3.4.3.3. Financials
      • 3.4.3.4. Recent Developments
      • 3.4.3.5. Analyst Perspective
    • 3.4.4. QIAGEN N.V.
      • 3.4.4.1. Company Overview
      • 3.4.4.2. Role of QIAGEN N.V. in the Emerging Infectious Disease Diagnostics Market
      • 3.4.4.3. Financials
      • 3.4.4.4. Recent Developments
      • 3.4.4.5. Analyst Perspective
    • 3.4.5. Tecan Trading AG
      • 3.4.5.1. Company Overview
      • 3.4.5.2. Role of Tecan Trading AG in the Emerging Infectious Disease Diagnostics Market
      • 3.4.5.3. Financials
      • 3.4.5.4. Recent Developments
      • 3.4.5.5. Analyst Perspective
    • 3.4.6. Siemens Healthineers AG
      • 3.4.6.1. Company Overview
      • 3.4.6.2. Role of Siemens Healthineers AG in the Emerging Infectious Disease Diagnostics Market
      • 3.4.6.3. Financials
      • 3.4.6.4. Recent Developments
      • 3.4.6.5. Analyst Perspective
  • 3.5. Company Snapshots
    • 3.5.1. En Carta Diagnostics
      • 3.5.1.1. Company Overview
      • 3.5.1.2. Role of En Carta Diagnostics in the Emerging Infectious Disease Diagnostics Market

List of Figures

  • Figure 1: Europe Emerging Infectious Disease Diagnostics Market (by Technology), $Billion, 2022-2033
  • Figure 2: Europe Emerging Infectious Disease Diagnostics Market, Impact Analysis
  • Figure 3: Europe Emerging Infectious Disease Diagnostics Market (by Technology), Share (%), 2022 and 2033
  • Figure 4: Europe Emerging Infectious Disease Diagnostics Market (by Application), Share (%), 2022 and 2033
  • Figure 5: Share of Key Developments, January 2019-June 2023
  • Figure 6: Market Share Analysis for Emerging Infectious Disease Diagnostics Market (by Company), 2022
  • Figure 7: Key Insights Validated from Primary Interviews
  • Figure 8: Emerging Infectious Disease Diagnostics Market Research Methodology
  • Figure 9: Primary Research Methodology
  • Figure 10: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 11: Top-Down Approach (Segment-Wise Analysis)
  • Figure 12: Timeline of Emerging Technologies for Infectious Disease Diagnostics
  • Figure 13: Advantages of Emerging Infectious Disease Diagnostic Technologies
  • Figure 14: Limitations of Emerging Infectious Disease Diagnostic Technologies
  • Figure 15: Key Settings of POC Testing Deployment
  • Figure 16: Key Challenges Associated with Point-of-Care Testing
  • Figure 17: Emerging Infectious Disease Diagnostics Market (by Technology), $Billion, 2022-2033
  • Figure 18: Future Potential of NGS in Infectious Disease Diagnostics
  • Figure 19: Number of Molecular Diagnostics Patents for Infectious Diseases (by Year)
  • Figure 20: Number of Molecular Diagnostic Patents for Infectious Diseases (by Country/Organization)
  • Figure 21: Key Benefits of Home-Based Testing
  • Figure 22: Typical Supply Chain for a Diagnostic Test
  • Figure 23: Emerging Infectious Disease Diagnostics Market, Impact Analysis
  • Figure 24: Fiscal Response to the COVID-19 Pandemic (% of GDP)
  • Figure 25: Advantages of Point-of-Care Tests in Molecular Diagnostics
  • Figure 26: Key Clinical Areas Demanding Commercial Availability of Syndromic Tests
  • Figure 27: Advantages of INAAT over PCR
  • Figure 28: Number of LAMP Publications on Public Databases, 2016-2022
  • Figure 29: Number of INAAT Publications on Public Databases, 2016-2022
  • Figure 30: Advantages of Digital PCR over Quantitative Real-Time PCR
  • Figure 31: Number of "Digital PCR" Publications on Public Databases, 2016-2022
  • Figure 32: Europe Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
  • Figure 33: Europe Emerging Infectious Disease Diagnostics Market (by Application), $Billion, 2022-2033
  • Figure 34: Europe Emerging Infectious Disease Diagnostics Market (by Technology), $Billion, 2022-2033
  • Figure 35: Europe Emerging Infectious Disease Diagnostics Market (by Type of Infection), $Billion, 2022-2033
  • Figure 36: Europe Emerging Infectious Disease Diagnostics Market (by Disease Type), $Billion, 2022-2033
  • Figure 37: Europe Emerging Infectious Disease Diagnostics Market (by End User), $Billion, 2022-2033
  • Figure 38: Europe Emerging Infectious Disease Diagnostics Market (by Country), % Share, 2022 and 2033
  • Figure 39: Germany Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
  • Figure 40: Germany Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033
  • Figure 41: U.K. Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
  • Figure 42: U.K. Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033
  • Figure 43: France Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
  • Figure 44: France Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033
  • Figure 45: Italy Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
  • Figure 46: Italy Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033
  • Figure 47: Spain Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
  • Figure 48: Spain Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033
  • Figure 49: Rest-of-Europe Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
  • Figure 50: Rest-of-Europe Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033
  • Figure 51: Share of Key Developments, January 2019-June 2023
  • Figure 52: Number of Mergers and Acquisitions (by Company), January 2019-June 2023
  • Figure 53: Share of Synergistic Activities (by Company), January 2019-June 2023
  • Figure 54: Number of Business Expansions and Funding Activities (by Company), January 2019-June 2023
  • Figure 55: Number of Product Launches/Upgradations/Approvals (by Company), January 2019-June 2023
  • Figure 56: Market Share Analysis for Emerging Infectious Disease Diagnostics Market (by Company), 2022
  • Figure 57: Emerging Infectious Disease Diagnostics Market, Total Number of Companies Profiled
  • Figure 58: bioMerieux S.A.: Product Portfolio
  • Figure 59: bioMerieux S.A.: Overall Financials, $Million, 2020-2022
  • Figure 60: bioMerieux S.A.: Revenue (by Segment), $Million, 2020-2022
  • Figure 61: bioMerieux S.A.: Revenue (by Region), $Million, 2020-2022
  • Figure 62: bioMerieux S.A.: R&D Expenditure, $Million, 2020-2022
  • Figure 63: DiaSorin S.p.A.: Product Portfolio
  • Figure 64: DiaSorin S.p.A.: Overall Financials, $Million, 2021-2022
  • Figure 65: DiaSorin S.p.A.: Revenue (by Region), $Million, 2021-2022
  • Figure 66: DiaSorin S.p.A.: R&D Expenditure, $Million, 2021-2022
  • Figure 67: F. Hoffmann-La Roche Ltd: Product Portfolio
  • Figure 68: F. Hoffmann-La Roche Ltd: Overall Financials, 2020-2022
  • Figure 69: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2020-2022
  • Figure 70: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2020-2022
  • Figure 71: QIAGEN N.V.: Product Portfolio
  • Figure 72: QIAGEN N.V.: Overall Financials, $Million, 2020-2022
  • Figure 73: QIAGEN N.V.: Revenue (by Segment), $Million, 2020-2022
  • Figure 74: QIAGEN N.V.: Revenue (by Region), $Million, 2020-2022
  • Figure 75: QIAGEN N.V.: R&D Expenditure, $Million, 2020-2022
  • Figure 76: Tecan Trading AG: Product Portfolio
  • Figure 77: Tecan Trading AG: Overall Financials, $Million, 2020-2022
  • Figure 78: Tecan Trading AG: Revenue (by Segment), $Million, 2020-2022
  • Figure 79: Tecan Trading AG: Revenue (by Region), $Million, 2020-2022
  • Figure 80: Tecan Trading AG: R&D Expenditure, $Million, 2020-2022
  • Figure 81: Siemens Healthineers AG: Product Portfolio
  • Figure 82: Siemens Healthineers AG: Overall Financials, $Million, 2020-2022
  • Figure 83: Siemens Healthineers AG: Revenue (by Segment), $Million, 2020-2022
  • Figure 84: Siemens Healthineers AG: Revenue (by Region), $Million, 2020-2022
  • Figure 85: Siemens Healthineers AG: R&D Expenditure, $Million, 2020-2022
  • Figure 86: En Carta Diagnostics: Overall Product Portfolio

List of Tables

  • Table 1: Some of the Key Developments By Companies Leveraging Emerging Technologies in Infectious Disease Diagnostics
  • Table 2: Key Product Offerings by Players in the Emerging Infectious Disease Diagnostics Market
  • Table 3: Key Questions Answered in the Report
  • Table 4: Some of the RT-LAMP Assays Developed during COVID-19
  • Table 5: Molecular Diagnostic Products for Infectious Diseases Under Development
  • Table 6: At-Home COVID-19 Kits Approved for Commercial Use by ICMR
  • Table 7: Examples of International Research Consortiums for Managing Response to Infectious Diseases
  • Table 8: List of Infectious Disease Outbreaks (by Region and Year)
  • Table 9: Europe Emerging Infectious Disease Diagnostics Market, Impact Analysis
  • Table 10: Emerging Infectious Disease Diagnostics Market, Key Active Players